ABSTRACT
A 62-year-old woman presented to a primary care doctor on January 2006 due to a sore throat and high fever, and had received medication for a common cold. She was referred to our hospital in February 2006 because of additional manifestations such as painful rashes on the lower limb similar to erythema nodosum and polyarthralgia on her feet, shoulder and finger joints. She was initially treated with an anti-inflammatory drug (NSAID) for polyarthritis but the symptoms did not improved. In addition, the serum level of anti-streptolysin O antibody (ASO) was elevated at the second visit more than that at the first visit. She was diagnosed to have rheumatic fever (RF) based on the polyarthritis, inflammatory data and an increase of the ASO level. She was treated with 10 mg a day of prednisolone (PSL) and sultamicillin tosilate. However, a systolic murmur that had been never noticed by previous auscultation appeared after the third hospital day and the mitral regurgitation was also detected on echocardiogram. She was then treated with 40 mg a day of PSL because of an appearance of the carditis due to RF. The increased PSL dose promptly improved the systolic murmur as well as the arthritis. This report presented an RF case with carditis detected by an development of the systolic murmur in an adult female.
Subject(s)
Myocarditis/complications , Rheumatic Heart Disease/complications , Systolic Murmurs/etiology , Ampicillin/administration & dosage , Autoantibodies/blood , Bacterial Proteins/immunology , Biomarkers/blood , Drug Therapy, Combination , Echocardiography , Female , Humans , Middle Aged , Mitral Valve Insufficiency/diagnostic imaging , Myocarditis/diagnosis , Myocarditis/drug therapy , Prednisolone/administration & dosage , Rheumatic Heart Disease/diagnosis , Rheumatic Heart Disease/drug therapy , Streptolysins/immunology , Sulbactam/administration & dosage , Systolic Murmurs/diagnosis , Systolic Murmurs/drug therapy , Treatment OutcomeABSTRACT
A 53-year-old woman was admitted due to akinetic mutism and fever. On admission, brain computed tomography (CT) scan revealed a large hemorrhagic lesion in the left anterior lobe that required surgical operation for total removal. Her neuropsychiatric manifestation was not attenuated after the operation, and was gradually ameliorated by high doses of corticosteroid thereafter, suggesting a diagnosis of lupus psychosis. Histopathological examination revealed a necrotizing vasculature, sometimes with a disrupted lamina elastica interna, completely filled with thrombi and infiltrated with inflammatory cells and their debris. It is therefore suggested that the large frontal lobe hematoma in our patient was induced by thrombosis and arteritis in the subarachnoid space.
Subject(s)
Antiphospholipid Syndrome/complications , Cerebral Hemorrhage/etiology , Cerebral Hemorrhage/pathology , Lupus Vasculitis, Central Nervous System/complications , Biopsy , Cerebral Hemorrhage/diagnostic imaging , Female , Humans , Intracranial Thrombosis/diagnostic imaging , Intracranial Thrombosis/etiology , Intracranial Thrombosis/pathology , Magnetic Resonance Imaging , Middle Aged , Tomography, X-Ray ComputedABSTRACT
Recent studies have shown the beneficial effect of infliximab in ocular manifestation of Behçet's disease. The current studies examined the efficacy of infliximab in progressive neuro-Behçet's syndrome (NB) refractory to methotrexate (MTX). Five male patients with progressive NB with sustained elevation of cerebrospinal fluid (CSF) IL-6 (over 20 pg/ml) despite administration of MTX and steroid, were given intravenous infusion of 5 mg/kg infliximab at weeks 0, 2, 6, and 14 with MTX (10-17.5 mg/week) and prednisolone (<10 mg/day) at the same doses. The clinical responses were judged by neuropsychiatric findings, revised Wechsler adult intelligence scale (WAIS-R), and brain magnetic resonance imaging (MRI) scans at 24 weeks. In all the 5 patients, CSF IL-6 were markedly decreased by 1/2-1/37 on the next day of the first infusion and remained below 20 pg/ml before the last infusion at 14 weeks, whereas CSF TNF-alpha were not significantly changed at any time point. At 24 weeks from the initial infusion, none of the 5 patients showed exacerbation (3 patients significantly improved). Nor did the atrophy in midbrain, pons and medulla on brain MRI scans show significant progression. These results suggest that infliximab might have a beneficial effect in the treatment of progressive NB by reducing CSF IL-6 levels but not TNF-alpha. Since infliximab has been shown to have cytotoxic effects on monocytes/macrophages, the rapid fall of CSF IL-6 after the infusion suggest that infliximab might directly act on such inflammatory cells producing IL-6.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Behcet Syndrome/drug therapy , Adult , Antibodies, Monoclonal/blood , Antibodies, Monoclonal/cerebrospinal fluid , Behcet Syndrome/metabolism , Behcet Syndrome/pathology , Brain/drug effects , Brain/pathology , Female , Humans , Infliximab , Interleukin-6/blood , Interleukin-6/cerebrospinal fluid , Magnetic Resonance Imaging/methods , Middle Aged , Time Factors , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/cerebrospinal fluidABSTRACT
We report two cases presenting focal neurological deficits with high intensity lesions in fluid attenuated inversion recovery (FLAIR) images on brain magnetic resonance imaging (MRI), which almost completely improved by corticosteroid therapy. Marked elevation of cerebrospinal fluid IL-6 was also noted when these patients showed neurological deficits. As far as we explored, there have been thirteen published case reports of systemic lupus erythematosus patients with reversible focal neurological deficits. The neurological symptoms varied from case to case, but could be attributed to the lesions on MRI scans. The completely reversible feature of neurological manifestations as well as MRI findings on corticosteroid therapy is distinct from any other disorder, including cerebrovascular disease and demyelinating syndrome, in the 1999 American College of Rheumatology nomenclature. Therefore, we propose that reversible focal neurological deficits should be added to the 1999 nomenclature and classification and case definitions.
Subject(s)
Lupus Erythematosus, Systemic/complications , Nervous System Diseases/etiology , Adult , Female , Humans , Lupus Erythematosus, Systemic/pathology , Magnetic Resonance Imaging/methods , Male , Nervous System Diseases/pathologySubject(s)
Behcet Syndrome/complications , Behcet Syndrome/immunology , HLA-B Antigens/immunology , Nervous System Diseases/etiology , Smoking/adverse effects , Adult , Aged , Behcet Syndrome/physiopathology , Disease Progression , Female , HLA-B51 Antigen , Humans , Male , Middle Aged , Risk FactorsSubject(s)
Behcet Syndrome/drug therapy , Methotrexate/therapeutic use , Adult , Aged , Behcet Syndrome/physiopathology , Behcet Syndrome/psychology , Dementia/etiology , Disease Progression , Drug Monitoring , Female , Follow-Up Studies , Humans , Immunosuppressive Agents/therapeutic use , Interleukin-6/cerebrospinal fluid , Male , Middle Aged , Paresis/etiology , Time Factors , Wechsler ScalesABSTRACT
Abstract We describe the case of a 29-year-old woman with systemic lupus erythematosus (SLE), who developed congestive heart failure and severe axonal polyneuropathy after 9 months of treatment with alfacalcidol for the prevention of corticosteroid-induced osteoporosis. There was no evidence for the exacerbation of SLE. Moreover, both congestive heart failure and axonal polyneuropathy improved after discontinuation of the alfacalcidol without increasing the dose of corticosteroid. Since alfacalcidol is commonly used in the prevention of corticosteroid-induced osteoporosis, rheumatologists should be aware of the presence of this life-threatening adverse effect.
ABSTRACT
Although sulfasalazine is a well-known disease-modifying antirheumatic drug (DMARD), the mechanisms of its action remain unclear. Indeed, it remains uncertain whether sulfasalazine itself or one of its metabolites is responsible for the antirheumatic effects of sulfasalazine. Since one of the characteristic features of rheumatoid arthritis (RA) is chronic stimulation of B cells, we compared the effects of sulfasalazine and its metabolites on the in vitro function of human B cells. Ig production was induced from highly purified B cells from healthy donors by stimulation with Staphylococcus aureus Cowan I (SA) plus IL-2. Sulfasalazine suppressed the production of IgM and IgG at its pharmacologically attainable concentrations (1-10 microg/ml). Of the metabolites of sulfasalazine, sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA), but not 4-acethyl SP, also significantly suppressed the production of IgM and IgG at their pharmacologically relevant concentrations. By contrast, any of sulfasalazine, SP, 5-ASA and 4-acethyl SP did not suppress the IFN-gamma production of immobilized anti-CD3 stimulated CD4+ T cells. These results indicate that sulfasalazine and its metabolites preferentially suppress the function of B cells, but not that of T cells, at their pharmacologically attainable concentrations. The data therefore suggest that not only sulfasalazine, but its metabolites, might contribute to the beneficial effects of sulfasalazine.